Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 804-814

  Eleftheriadou, V ^a   Thomas, K S ^a   Whitton, M E ^a   Batchelor, J M ^b   Ravenscroft, J C ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE;

ADVERSE DRUG REACTION; BLISTER; BODY IMAGE; CELL CULTURE; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; ENZYME ACTIVITY; HEALTH SURVEY; HISTOLOGY; HUMAN; META ANALYSIS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPIGMENTATION; REVIEW; SELF ESTEEM; SKIN COLOR; SKIN PIGMENTATION; STRESS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VITILIGO;

ADULT; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHYSICIANS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SKIN PIGMENTATION; TREATMENT OUTCOME; VITILIGO;

EID: 84867005790     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11056.x     Document Type: Review

References (69)

1. Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev 2010; 1: CD003263.
2. COMET Initiative. Core Outcome Measures in Effectiveness Trials. Available at: http://www.comet-initiative.org (last accessed 11 June 2012).
3. Taieb A, Picardo M,. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27-35.
4. Gonzalez U, Whitton M, Eleftheriadou V, et al. Guidelines for designing and reporting clinical trials in vitiligo. Arch Dermatol 2011; 147: 1428-36.
5. Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012; 25: E1-13.
6. Tugwell P, Boers M, Brooks P, et al. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007; 8: 38.
7. Sinha I, Jones L, Smyth RL, et al. A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. PLoS Med 2008; 5: e96.
8. Lerner AB, Nordlund JJ,. Vitiligo. What is it? Is it important? JAMA 1978; 239: 1183-7.
9. Townshend AP, Chen CM, Williams HC,. How prominent are patient-reported outcomes in clinical trials of dermatological treatments? Br J Dermatol 2008; 159: 1152-9.
10. Eleftheriadou V, Whitton ME, Gawkrodger DJ, et al. Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br J Dermatol 2011; 164: 530-6.
11. Kumaran MS, Kaur I, Kumar B,. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 269-73.
12. Bhatnagar A, Kanwar AJ, Parsad D, et al. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol 2007; 21: 638-42.
13. Tegta GR, Parsad D, Majumdar S, et al. Efficacy of autologous transplantation of noncultured epidermal suspension in two different dilutions in the treatment of vitiligo. Int J Dermatol 2006; 45: 106-10.
14. Yones SS, Palmer RA, Garibaldinos TM, et al. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol 2007; 143: 578-84.
15. Sanclemente G, Garcia JJ, Zuleta JJ, et al. A double-blind, randomized trial of 0·05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008; 22: 1359-64.
16. Papadopoulos L, Walker C, Anthis L,. Living with vitiligo: a controlled investigation into the effects of group cognitive-behavioural and person-centred therapies. Dermatol Psychosom 2004; 5: 172-7.
17. Charman C, Chambers C, Williams H,. Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol 2003; 120: 932-41.
18. Chalmers I, Glasziou P,. Avoidable waste in the production and reporting of research evidence. Lancet 2009; 374: 86-9.
19. Anbar TS, Westerhof W, Abdel-Rahman AT, et al. Effect of one session of ER:YAG laser ablation plus topical 5Fluorouracil on the outcome of short-term NB-UVB phototherapy in the treatment of non-segmental vitiligo: a left-right comparative study. Photodermatol Photoimmunol Photomed 2008; 24: 322-9.
20. Arca E, Tastan HB, Erbil AH, et al. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006; 33: 338-43.
21. Asawanonda P, Kijluakiat J, Korkij W, et al. Targeted broadband ultraviolet B phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study. Acta Derm Venereol (Stockh) 2008; 88: 376-81.
22. Barman KD, Khaitan BK, Verma KK,. A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo. Dermatol Surg 2004; 30: 49-53.
23. Casacci M, Thomas P, Pacifico A, et al. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo-a multicentre controlled study. J Eur Acad Dermatol Venereol 2007; 21: 956-63.
24. Cestari TF, Dias MS, Fernandes EI, Albaneze R,. Comparative study of two psoralens in topical phototherapy for vitiligo [Estudo comparativo entre dois psoralenos na fototerapia topica do vitiligo]. An Bras Dermatol 2001; 76: 683-92.
25. Czajkowski R,. Comparison of melanocytes transplantation methods for the treatment of vitiligo. Dermatol Surg 2004; 30: 1400-5.
26. Dawid M, Veensalu M, Grassberger M, Wolff K,. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study [Wirksamkeit und Sicherheit von Pimecrolimus-Creme 1% bei erwachsenen Patienten mit Vitiligo: Ergebnisse einer randomisierten, Vehikel-kontrollierten Doppelblind-Studie]. J Dtsch Dermatol Ges 2006; 4: 942-6.
27. Dell'Anna ML, Mastrofrancesco A, Sala R, et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol 2007; 32: 631-6.
28. El-Mofty M, Mostafa W, Youssef R, et al. Ultraviolet A in vitiligo. Photodermatol Photoimmunol Photomed 2006; 22: 214-16.
29. Ermis O, Alpsoy E, Cetin L, et al. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001; 145: 472-5.
30. Esfandiarpour I, Ekhlasi A, Farajzadeh S, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009; 20: 14-18.
31. Farah FS, Kurban AK, Chaglassian HT,. The treatment of vitiligo with psoralens and triamcinolone by mouth. Br J Dermatol 1967; 79: 89-91.
32. Goldinger SM, Dummer R, Schmid P, et al. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007; 21: 504-8.
33. Hamzavi I, Jain H, McLean D, et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol 2004; 140: 677-83.
34. Hofer A, Hassan AS, Legat FJ, et al. Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br J Dermatol 2005; 152: 981-5.
35. Kandil E,. Treatment of vitiligo with 0·1 per cent betamethasone 17-valerate in isopropyl alcohol-a double-blind trial. Br J Dermatol 1974; 91: 457-60.
36. Kawalek AZ, Spencer JM, Phelps RG,. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30: 130-5.
37. Khalid M, Mujtaba G, Haroon TS,. Comparison of 0·05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. Int J Dermatol 1995; 34: 203-5.
38. Khandpur S, Sharma VK, Manchanda Y,. Comparison of minipunch grafting versus split-skin grafting in chronic stable vitiligo. Dermatol Surg 2005; 31: 436-41.
39. Leone G, Pacifico A, Iacovelli P, et al. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol 2006; 31: 200-5.
40. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0·1% tacrolimus vs 0·05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
41. Lim-Ong M, Leveriza RM, Ong BE, Frez ML,. Comparison between narrow-band UVB with topical corticosteroid and narrow-band UVB with placebo in the treatment of vitiligo: a randomized controlled trial. J Philipp Dermatol Soc 2005; 14: 17-22.
42. Lu-yan T, Wen-wen F, Lei-hong X, et al. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2006; 22: 310-14.
43. Mehrabi D, Pandya AG,. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0·1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006; 142: 927-9.
44. Middelkamp-Hup MA, Bos JD, Rius-Diaz F, et al. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2007; 21: 942-50.
45. Navarro JR, Canames AA, el al Salado Ponce H,. Autologous skin minigraft and ingestion of 8-methoxypsoralen in patients with stable vitiligo vulgaris. Dermatologia Rev Mex 2002; 42: 260-7.
46. Ozdemir M, Cetinkale O, Wolf R, et al. Comparison of two surgical approaches for treating vitiligo: a preliminary study. Int J Dermatol 2002; 41: 135-8.
47. Parsad D, Saini R, Verma N,. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998; 197: 167-70.
48. Parsad D, Pandhi R, Juneja A,. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 2003; 28: 285-7.
49. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-9.
50. Pathak MA, Mosher DB, Fitzpatrick TB,. Safety and therapeutic effectiveness of 8-methoxypsoralen, 4,5',8-trimethylpsoralen, and psoralen in vitiligo. Natl Cancer Inst Monogr 1984; 66: 165-73.
51. Procaccini EM, Riccio G, Monfrecola G,. Ineffectiveness of topical khellin in photochemotherapy of vitiligo. J Dermatolog Treat 1995; 6: 117-20.
52. Radmanesh M, Saedi K,. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat 2006; 17: 151-3.
53. Rath N, Kar HK, Sabhnani S,. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol 2008; 74: 357-60.
54. Reyes E, Jaen P, de las Heras E, et al. Systemic immunomodulatory effects of Polypodium leucotomos as an adjuvant to PUVA therapy in generalized vitiligo: a pilot study. J Dermatol Sci 2006; 41: 213-16.
55. Rodriguez-Martin M, Garcia Bustinduy M, Saez Rodriguez M, et al. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 2009; 160: 409-14.
56. Rojas-Urdaneta JE, Poleo-Romero AG,. Evaluation of an antioxidant and mitochondrial stimulating cream formula in the skin of patients with stable vulgar vitiligo [Evaluacion de una formulacion antioxidante y estimuladora mitocondrial en piel de pacientes con vitiligo vulgar estable]. Invest Clin 2007; 48: 21-31.
57. Ruiz Maldonado R, Tamayo Sanchez L,. 4-5-8 Trimethylpsoralen in vitiligo. Controlled study of its therapeutic and toxic effect in children [4-5-8 Trimetilpsoralen en vitiligo. Estudio controlado de su efecto terapeutico y toxico en los ninos]. Actas Dermosifiliogr 1975; 66: 513-26.
58. Sassi F, Cazzaniga S, Tessari G, et al. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol 2008; 159: 1186-91.
59. Schallreuter KU, Moore J, Behrens-Williams S, et al. Rapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS). Int J Dermatol 2002; 41: 482-7.
60. Siddiqui AH, Stolk LM, Bhaggoe R, et al. l-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology 1994; 188: 215-18.
61. Shi N, Chen YJ, Wang J, et al. Clinical observation on the effect of Zengse Pill in treating patients with vitiligo of qi-stagnancy and blood-stasis syndrome type. Chin J Integr Med 2008; 14: 303-6.
62. Tjioe M, Gerritsen MJ, Juhlin L, et al. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol (Stockh) 2002; 82: 369-72.
63. van Geel N, Ongenae K, de Mil M, et al. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol 2004; 140: 1203-8.
64. Vasistha LK, Singh G,. Vitiligo and intralesional steroids. Indian J Med Res 1979; 69: 308-11.
65. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135: 1061-6.
66. Agarwal S, Ramam M, Sharma VK, et al. A randomized placebo-controlled double-blind study of levamisole in the treatment of limited and slowly spreading vitiligo. Br J Dermatol 2005; 153: 163-6.
67. Twiss J, Meads DM, Preston EP, et al. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol 2012; 132: 76-84.
68. Fernandez-Penas P, Jones-Caballero M, Espallardo O, Garcia-Diez A,. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. Br J Dermatol 2012; 166: 884-7.
69. Bhor U, Pande S,. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol 2006; 72: 315-21.